Literature DB >> 8363385

Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

R Nau1, H W Prange, P Muth, G Mahr, S Menck, H Kolenda, F Sörgel.   

Abstract

Cefotaxime and ceftriaxone have proven to be effective in pyogenic infections of the central nervous system. Since in some bacterial central nervous system infections the blood-cerebrospinal fluid (CSF) barrier is either minimally impaired or recovers in the course of the illness, we studied the penetration of both antibiotics in the absence of inflamed meninges. Patients who had undergone external ventriculostomies for noninflammatory occlusive hydrocephalus received either cefotaxime (2 g/30 min) or ceftriaxone (2 g/30 min) to treat extracerebral infections. Serum and CSF were drawn repeatedly after the first dose. With ceftriaxone, they were also drawn after the last dose. The concentrations of cefotaxime, its metabolite desacetylcefotaxime, and ceftriaxone were determined by high-performance liquid chromatography with UV detection. Maximum concentrations of cefotaxime in CSF were reached 0.5 to 8 h (median = 3 h; n = 6) after the end of the infusion and ranged from 0.14 to 1.81 mg/liter (median = 0.44 mg/liter; n = 6). Maximum levels of ceftriaxone in CSF ranging from 0.18 to 1.04 mg/liter (median = 0.43 mg/liter; n = 5) were seen 1 to 16 h (median = 12 h; n = 5) after the infusion. The elimination half-life of cefotaxime in CSF was 5.0 to 26.9 h (median = 9.3 h; n = 5), and that of ceftriaxone was 15.7 to 18.4 h (median = 16.8 h; n = 3). It is concluded that after a single dose of 2 g, maximal concentrations of cefotaxime and ceftriaxone in CSF do not differ substantially. The long elimination half-lives guarantee uniform concentrations in CSF. These concentrations reliably inhibit highly susceptible bacteria but cannot be relied on to inhibit staphylococci and penicillin G-resistant Streptococcus pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363385      PMCID: PMC188005          DOI: 10.1128/AAC.37.7.1518

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Use of antibacterial agents in infections of the central nervous system.

Authors:  D Thea; M Barza
Journal:  Infect Dis Clin North Am       Date:  1989-09       Impact factor: 5.982

2.  Antibacterial activity of cefotaxime, desacetylcefotaxime, and the combination of the two.

Authors:  H Friis
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

3.  Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

Authors:  H Reiber; K Felgenhauer
Journal:  Clin Chim Acta       Date:  1987-03-30       Impact factor: 3.786

4.  Evidence for a slow elimination phase for penicillin G.

Authors:  S C Ebert; J Leggett; B Vogelman; W A Craig
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

5.  Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials.

Authors:  M H Lebel; B J Freij; G A Syrogiannopoulos; D F Chrane; M J Hoyt; S M Stewart; B D Kennard; K D Olsen; G H McCracken
Journal:  N Engl J Med       Date:  1988-10-13       Impact factor: 91.245

6.  Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group.

Authors:  H Peltola; M Anttila; O V Renkonen
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

7.  The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.

Authors:  A M Emmerson; P A Lamport; D S Reeves; M J Bywater; H A Holt; R Wise; J Andrews; M J Hall
Journal:  Curr Med Res Opin       Date:  1985       Impact factor: 2.580

8.  Low blood-to-cerebrospinal fluid passage of sorbitol after intravenous infusion.

Authors:  R Nau; T Dreyhaupt; H Kolenda; H W Prange
Journal:  Stroke       Date:  1992-09       Impact factor: 7.914

9.  Treatment of bacterial meningitis with once daily ceftriaxone therapy.

Authors:  W M Dankner; J D Connor; M Sawyer; R Straube; S A Spector
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

10.  Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis.

Authors:  J P Bryan; H Rocha; H R da Silva; A Taveres; M A Sande; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

View more
  49 in total

Review 1.  Glutamate transporter 1: target for the treatment of alcohol dependence.

Authors:  P S S Rao; Y Sari
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Adenosine and glutamate signaling in neuron-glial interactions: implications in alcoholism and sleep disorders.

Authors:  Hyung W Nam; Sally R McIver; David J Hinton; Mahesh M Thakkar; Youssef Sari; Fiona E Parkinson; Phillip G Haydon; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2012-02-06       Impact factor: 3.455

3.  [Syphilis treatment. German and international guidelines--a comparison].

Authors:  H Schöfer
Journal:  Hautarzt       Date:  2005-02       Impact factor: 0.751

4.  Antibiotics that protect the brain.

Authors:  David Secko
Journal:  CMAJ       Date:  2005-02-15       Impact factor: 8.262

Review 5.  Lyme disease--current state of knowledge.

Authors:  Roland Nau; Hans-Jürgen Christen; Helmut Eiffert
Journal:  Dtsch Arztebl Int       Date:  2009-01-30       Impact factor: 5.594

Review 6.  Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics.

Authors:  R Nau; H W Prange
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

7.  Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Authors:  Yanli Zhao; Merit E Cudkowicz; Jeremy M Shefner; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jerold S Harmatz; David Schoenfeld; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2014-05-16       Impact factor: 3.126

8.  Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro.

Authors:  Paolo Ruzza; Giuliano Siligardi; Rohanah Hussain; Anna Marchiani; Mehmet Islami; Luigi Bubacco; Giovanna Delogu; Davide Fabbri; Maria A Dettori; Mario Sechi; Nicolino Pala; Ylenia Spissu; Rossana Migheli; Pier A Serra; GianPietro Sechi
Journal:  ACS Chem Neurosci       Date:  2013-10-24       Impact factor: 4.418

Review 9.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 10.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.